Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. Co. is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Co. pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. We show 41 historical shares outstanding datapoints in our coverage of LXRX's shares outstanding history.
Understanding the changing numbers of LXRX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like LXRX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching LXRX by allowing them to research LXRX shares outstanding history
as well as any other stock in our coverage universe. |
Free LXRX Email Alerts:
Video: Shares Outstanding Importance
